Business Context and Reporting Period
Company: Omeros Corporation (OMER)
Filing Type: Form 8-K (Current Report)
Date of Report: March 13, 2023
Reporting Period: This filing announces financial results for the three months and the full year ended December 31, 2022. The specific financial data is contained in a press release furnished as Exhibit 99.1, which is incorporated by reference.
Key Financial Metrics
The provided text is a cover sheet for the Form 8-K and does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are detailed in the referenced press release (Exhibit 99.1) which is not included in the input text.
Material Changes
The filing text does not provide specific details regarding material changes versus prior periods. It serves solely to notify the market of the issuance of the financial results press release.
Guidance, Outlook, and Risks
Management Commentary: The report was signed by Gregory A. Demopulos, M.D., President, CEO, and Chairman of the Board.
Legal Disclaimer: The filing explicitly states that the information contained herein, including the exhibit, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to liability under that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933. Furthermore, this information shall not be incorporated by reference into any other SEC filing by Omeros Corporation.
Guidance and Risks: No specific guidance, outlook, or risk factors are detailed in the provided text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated March 13, 2023) for actual revenue, net loss, and cash position figures.
- Verify the specific performance of the company's drug candidates (e.g., OMT-101, OMT-102) as detailed in the full press release.
- Confirm the company's cash runway and any recent financing activities mentioned in the full results.
- Note the legal disclaimer regarding the non-incorporation of this specific 8-K text into future filings.